Prothena

About:

Prothena is a clinical-stage neuroscience company focused on the discovery and development of novel therapies.

Website: http://prothena.com

Top Investors: Sofinnova Investments

Description:

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a pipeline of novel investigational therapeutics with the potential to change the course of devastating rare peripheral amyloid and neurodegenerative diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases.

Total Funding Amount:

$505M

Estimated Revenue Range:

$50M to $100M

Headquarters Location:

South San Francisco, California, United States

Founded Date:

2012-01-01

Contact Email:

info(AT)Prothena.com

Founders:

Dennis Selkoe

Number of Employees:

101-250

Last Funding Date:

2022-12-14

IPO Status:

Public

© 2025 bioDAO.ai